Pharmacotherapy of type 2 diabetes mellitus: Navigating current and new therapies

MEDSURG Nursing

Volumn 24, Issue 6, 2015, Pages

  Lew, Kelley Newlin ^a   Wick, Allison ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ANALYSIS; DIABETES MELLITUS, TYPE 2; EDUCATION; GLUCOSE BLOOD LEVEL; HUMAN; NURSING; NURSING EDUCATION; NURSING STAFF;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EDUCATION, NURSING, CONTINUING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; NURSING STAFF;

EID: 84995360038     PISSN: 10920811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. American Diabetes Association (ADA). (2015). Standards of medical care in diabetes-2015. Diabetes Care, 38(Suppl. 1), S1-S93.
2. Amin, M., & Suksomboon, N. (2014). Pharmacotherapy of type 2 diabetes mellitus: An update on drug-drug interactions. Drug Safety, 37(11), 903-919. doi: 10. 1007/s40264-014-0223-2
3. Astra Zeneca. (2015a). Onglyza® (saxagliptin). Full prescribing information. Wilmington, DE: Author. Retrieved from http://www. azpicentral. com/onglyza/pi-onglyza. pdf #page=1
4. Astra Zeneca. (2015b). Farxiga® (dapagli-flozin). Full prescribing information. Wilmington, DE: Author. Retrieved from http://www1. astrazeneca-us. com/pi/ pi-farxiga. pdf
5. Bailey, C. J., Morales Villegas, E. C., Woo, V., Tang, W., Ptaszynska, A., & List, J. F. (2015). Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: A randomized doubleblind placebo-controlled 102-week trial. Diabetic Medicine, 32(4), 531-541.
6. Barnard, K., Batch, B., & Lien, L. F. (2011). Subcutaneous insulin: A guide for dosing regimens in the hospital. In L. Lien (Ed.), Glycemic control in the hospitalized patient (pp. 7-16): New York, NY: Springer-Verlag.
7. Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., EMPAREG RENAL Trial Investigators. (2014). Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinology, 2(5), 369-384.
8. Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Bolen, S. (2011). Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Annals of Internal Medicine, 154, 602-613.
9. Blonde, L., & San Juan, Z. T. (2012). Fixeddose combinations for treatment of type 2 diabetes mellitus. Advances in Therapy, 29(1), 1-13.
10. Bode, B., Stenlof, K., Harris, S., Sullivan, D., Fung, A., Usiskin, K., & Meininger, G. (2015). Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes, Obesity and Metabolism, 17(3), 294-303.
11. Boehringer Ingelheim. (2015). Tradjenta® (linagliptin). Full prescribing information. Ridgefield, CT: Author. Retrieved from http://docs. boehringer-ingelheim. com/ Prescribing%20Information/PIs/Tradjenta / Tradjenta. pdf
12. Bolinder, J., Ljunggren, O., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Parikh, S. (2012). Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. Journal of Clinical Endocrinology and Metabolism, 97(3), 1020-1031.
13. Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010). Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popu-lation Health Metrics, 8(1), 29. doi:10. 1186/1478-7954-8-29
14. Bristol-Myers Squibb Company. (2009). Glucophage (metformin hydrochloride) and Glucophage XR (metformin hydro-chloride extended-release). Full prescribing information. Princeton, NJ: Author. Retrieved from http://package inserts. bms. com/pi/pi-glucophage. pdf
15. Brown, D. X., & Evans, M. (2012). Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: A pharmacological perspective. Journal of Nutrition and Metabolism, 1-10. [Epub 20012, Oct. 18]. doi:10. 1155/2012/381713.
16. Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. (2013). A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care, 36(7), 2118-2125.
17. Cefalu, W. T., Leiter, L. A., de Bruin, T. W., Gause-Nilsson, I., Sugg, J., & Parikh, S. J. (2015). Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care, 38(7), 1218-1227.
18. Cefalu, W. T., Leiter, L. A., Yoon, K. H., Arias, P., Niskanen, L., Xie, J., Meininger, G. (2013). Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATASU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet, 382(9896), 941-950.
19. Centers for Disease Control and Prevention (CDC). (2013). Trends in diabetes and risk factors. Diagnosed diabetes among adults. Retrieved from http://www. cdc. gov/diabetes/atlas/obesityrisk/atlas. html Centers for Disease Control and Prevention
20. (CDC). (2014a). National diabetes statistics report: Estimates of diabetes and its burden in the United States, 2014. Retrieved from http://www. cdc. gov/ diabetes/pubs/statsreport14/nationaldiabetes-report-web. pdf Centers for Disease Control and Prevention
21. (CDC). (2014b). National chronic kidney disease fact sheet 2014. Retrieved from http://www. cdc. gov/diabetes/pubs/pdf/ kidney-Factsheet. pdf
22. Dailey, G. (2011). Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. Clinical Thera-peutics, 33(6), 665-678. doi:10. 1016/ j. clinthera. 2011. 04. 025
23. DeFronzo, R. A. (2011). Bromocriptine: A sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care, 34(4), 789-794.
24. DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Griffen, S. C. (2013). Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care, 36(10), 3169-3176.
25. Del Prato, S., Nauck, M., Duran-Garcia, S., Maffei, L., Rohwedder, K., Theuerkauf, A., & Parikh, S. (2015). Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in type 2 diabetes patients: 4-year data. Diabetes, Obesity and Metabolism, 17(6), 581-590. doi:10. 1111/dom. 12459
26. Dicker, D. (2011). DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors. Diabetes Care, 34(Suppl. 2), S276-278.
27. Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010). Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits. Diabetes Care, 33(2), 428-433.
28. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Huang, G. D. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine, 360(2), 129-139. doi: 10. 1056/ NEJMoa0808431
29. Eli Lilly and Company. (2015). Jardiance® (empagliflozin). Full prescribing information. Indianapolis, IN: Author. Retrieved from http://docs. boehringer-ingelheim. com/Prescribing%20Information/PIs/ Jardiance/jardiance. pdf
30. Ferrannini, E., Berk, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H. J., & Broedl, U. C. (2013). Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care, 36(12), 4015-4021.
31. Fonseca, V. A., Handelsman, Y., & Staels, B. (2010). Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence. Diabetes, Obesity and Metabolism, 12(5), 384-392.
32. Gaede, P., Lund-Andersen, H., Parving, H. H., & Pedersen, O. (2008). Effect of a multifactorial intervention on mortality in type 2 diabetes: Results and projections from the Steno-2 study. New England Journal of Medicine, 358(6), 580-591. doi: 10. 1056/NEJMoa0706245
33. Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Davidson, M. H. (2015). American Association of Clinical Endocrinologists/American College of Endocrinology comprehensive diabetes management algorithm. Endocrine Practice, 21(4), e1-e10.
34. Garcia-Perez, L. E., Alvarez, M., Dilla, T., Gil-Guillen, V., & Orozco-Beltran, D. (2013). Adherence to therapies in patients with type 2 diabetes. Diabetes Therapy, 4(2), 175-194.
35. Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, D. C., Jr., Bigger, J. T., Buse, J. B., Friedewald, W. T. (2008). Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine, 358(24), 2545-2559. doi: 10. 1056/NEJM oa0802743
36. Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., TECOS Study Group. (2015). Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 373(3), 232-242. doi: 10. 1056/ NEJMoa1501352
37. Handelsman, Y., Bloomgarden, Z. T., Grun-berger, G., Umpierrez, G. E., Zimmerman, R. S., Bailey, T., Zangeneh, F. (2015). American Asso ciation of Clinical Endo-crinologists and American College of Endocrinology clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. Endocrine Practice, 21(Suppl. 1), 1-87.
38. Hemmingsen, B., Schroll, J. B., Wetterslev, J., Gluud, C., Vaag, A., Sonne, D. P., Almdal, T. (2014). Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: A Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open, 2(3), E162-175. doi: 10. 9778/cmajo. 20130073
39. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359(15), 1577-1589.
40. Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Matthews, D. R. (2015). Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38(1), 140-149.
41. Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014). Metformin in patients with type 2 diabetes and kidney disease: A systematic review. Journal of the American Medical Association, 312(24), 2668-2675. doi: 10. 1001/jama. 2014. 15298
42. Janssen Pharmaceuticals. (2015). Invokana® (canagliflozin). Full prescribing information. Titusville, NJ: Author. Retrieved from https://www. janssenmd. com/pdf/ invokana/PI-INVOKANA. pdf
43. Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet, 383(9922), 1068-1083.
44. Khunti, K., Wolden, M. L., Thorsted, B. L., Andersen, M., & Davies, M. J. (2013). Clinical inertia in people with type 2 diabetes: A retrospective cohort study of more than 80, 000 people. Diabetes Care, 36(11), 3411-3417.
45. Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014). Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney International, 85(4), 962-971.
46. Leiter, L. A., Cefalu, W. T., de Bruin, T. W., Gause-Nilsson, I., Sugg, J., & Parikh, S. J. (2014). Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: A 24-week, multicenter, ran domized, double-blind, placebo-controlled study with a 28-week extension. Journal of the American Geriatrics Society, 62(7), 1252-1262.
47. List, J. F., & Whaley, J. M. (2011). Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney International, 79(Suppl. 120), S20-S27.
48. Look Ahead Research Group. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine, 369(2), 145-154.
49. Merck & Co. (2015). Januvia® (sitagliptin). Full prescribing information. Whitehouse Station, NJ: Author. Retrieved from http://www. merck. com/product/usa/pi- circulars/j/januvia/januvia-pi. pdf
50. National Institutes of Health. (2015). Multi-center trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). Retrieved from http://clinicaltrials. gov/ ct2/show/NCT01730534?term=declare& rank=2
51. Nauck, M. A. (2011). Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications. American Journal of Medicine, 124(Suppl. 1), S3-S18.
52. Nauck, M. A. (2013). A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care, 36(7), 2126-2132.
53. Nauck, M. A. (2014). Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Design, Development and Therapy, 8, 1335-1380.
54. Nauck, M. A., Baranov, O., Ritzel, R. A., & Meier, J. J. (2013). Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia, 56(9), 1878-1883.
55. Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Stein, P., Matthews, D. (2013). Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebocontrolled trial. American Heart Journal, 166(2), 217-223 e211.
56. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Travert, F. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358(24), 2560-2572. doi:10. 1056/NEJMoa0802987
57. Reid, T. S. (2012). Choosing GLP-1 receptor agonists or DPP-4 inhibitors: Weighing the clinical trial evidence. Clinical Diabetes, 30(1), 3-12.
58. Saisho, Y. (2014). Importance of beta cell function for the treatment of type 2 diabetes. Journal of Clinical Medicine, 3(3), 923-943. doi:10. 3390/jcm3030923
59. Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., the Savor-Timi Steering Committee Investi-gators. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine, 369(14), 1317-1326.
60. Selvin, E., Parrinello, C. M., Sacks, D. B., & Coresh, J. (2014). Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Annals of Internal Medicine, 160(8), 517-525. doi:10. 7326/M13-2411
61. Skugor, M. (2014). Diabetes mellitus treatment. Retrieved from http://www. cleve landclinicmeded. com/medicalpubs/ diseasemanagement/endocrinology/ diabetes-mellitus-treatment/Default. htm
62. Takeda Pharmaceuticals America, Inc. (2015). Nesina® (alogliptin). Full prescribing information. Deerfield, IL: Author. Re-trieved from http://www. accessdata. fda. gov/drugsatfda-docs/label/2013/ 022271s000lbl. pdf
63. Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015). GLP-1 receptor agonists: A review of head-to-head clinical studies. Thera-peutic Advances in Endocrinology and Metabolism, 6(1), 19-28. doi:10. 1177/ 2042018814559725
64. Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Tsapas, A. (2013). Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and metaanalysis. Annals of Internal Medicine, 159(4), 262-274.
65. Viollet, B., Guigas, B., Sanz Garcia, N., Leclerc, J., Foretz, M., & Andreelli, F. (2012). Cellular and molecular mechanisms of metformin: An overview. Clinical Science (Lond), 122(6), 253-270.
66. Walia, R. (2012). Insulin therapy. In Y. Munjal (Ed.), API textbook of medicine (9th ed.). Mumbai, India: Association of Physicians of India.
67. White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., the Examine Investigators. (2013). Alogliptin after acute coronary syndrome in patients with type 2 diabetes. New England Journal of Medicine, 369(14), 1327-1335.
68. Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Look Ahead Research Group. (2011). Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care, 34(7), 1481-1486.
69. Yale, J. F., Bakris, G., Cariou, B., Yue, D., David-Neto, E., Xi, L., Meininger, G. (2013). Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 15(5), 463-473.
70. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., the EMPA-REG OUTCOME Investigators. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. Epub ahead of print.